Antihyperuricemic and xanthine oxidase inhibitory activities of Tribulus arabicus and its isolated compound, ursolic acid: In vitro and in vivo investigation and docking simulations
Open Access
- 16 August 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (8), e0202572
- https://doi.org/10.1371/journal.pone.0202572
Abstract
Hyperurecemia is usually associated with gout and various metabolic arthritis disorders. Limited medications are available to manage such conditions. This study aimed to isolate the triterpenes constituent of the plant and to assess xanthine oxidase (XO) inhibitory and antihyperuricemic activities of Tribulus arabicus ethanolic extract, its fractions and the isolated compound using in vitro and in vivo approaches. The ethanolic extract, fractions; n-hexane, chloroform and n-butanol and the isolated compound (ursolic acid) were evaluated in vitro for their XO inhibitory activity. Those that demonstrated significant activity were further evaluated for their antihyperuricemic activity on potassium oxonate-induced hyperuricemia in mice. The ethanolic extract was found to be safe up to 5000 mg/kg. The extract and its n-hexane fraction exhibited significant inhibitory activity on XO, whilst only a modest reduction in the enzymatic activity was noticed with n-butanol and chloroform fractions. Furthermore, administration of the ethanolic extract at low and high doses significantly reduced serum urate levels in mice by 31.1 and 64.6% respectively. The isolated active constituent, ursolic acid, showed potent XO inhibition activity (Half maximal inhibitory concentration, IC50 = 10.3 μg/mL), and significantly reduced uric acid level in vivo by 79.9%. Virtually, the binding mode of ursolic acid with XO was determined using molecular docking simulations. The activity of the ethanolic extract of T. arabicus and its n-hexane fraction can be attributed to the isolated compound, ursolic acid. Ursolic acid has good hypouricemic activity and therefore has high potential to be used for the treatment of gout and hyperuricemia-related diseases.This publication has 33 references indexed in Scilit:
- Nephroprotective Effect of Ursolic Acid in a Murine Model of Gentamicin-Induced Renal DamageISRN Pharmacology, 2012
- Synthesis, biology and clinical significance of pentacyclic triterpenes: a multi-target approach to prevention and treatment of metabolic and vascular diseasesNatural Product Reports, 2011
- Antioxidant, antihyperuricemic and xanthine oxidase inhibitory activities ofHyoscyamus reticulatusPharmaceutical Biology, 2010
- Preparation and Body Distribution of Freeze-Dried Powder of Ursolic Acid Phospholipid NanoparticlesDrug Development and Industrial Pharmacy, 2009
- Mechanism of Inhibition of Xanthine Oxidoreductase by Allopurinol: Crystal Structure of Reduced Bovine Milk Xanthine Oxidoreductase Bound with OxipurinolNucleosides, Nucleotides and Nucleic Acids, 2008
- Antibacterial and antifungal activities of different parts of Tribulus terrestris L. growing in IraqJournal of Zhejiang University-SCIENCE B, 2008
- Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of AllopurinolPharmacological Reviews, 2006
- An Extremely Potent Inhibitor of Xanthine OxidoreductaseJournal of Biological Chemistry, 2003
- Successful desensitization of a fixed drug eruption caused by allopurinolJournal of Allergy and Clinical Immunology, 1998
- Archives of Toxicology, 1983